首页 | 本学科首页   官方微博 | 高级检索  
检索        

腔内修复或药物治疗稳定型B型主动脉夹层
引用本文:王江云,陈勇,李彦豪,何晓峰,曾庆乐,赵剑波.腔内修复或药物治疗稳定型B型主动脉夹层[J].介入放射学杂志,2017,26(3).
作者姓名:王江云  陈勇  李彦豪  何晓峰  曾庆乐  赵剑波
作者单位:南方医科大学南方医院介入放射科,广州,510515
摘    要:目的 比较胸主动脉腔内修复术(TEVAR)联合药物及单纯药物在稳定型Standford B型主动脉夹层治疗中的价值,探讨稳定型B型主动脉夹层治疗策略.方法 回顾性分析2004年至2015年收治的118例明确诊断为稳定型B型主动脉夹层患者临床资料,其中接受TEVAR联合药物治疗(TEVAR组)57例,单纯药物治疗(药物组)61例.分别统计1个月内、随访期并发症和死亡率,Kaplan-Meier生存曲线比较两组生存率.结果 术后1个月内及住院期间主要并发症发生率、死亡率,TEVAR组分别为5.2%、0%,药物组均为0%.术后随访1~110个月,平均(43.3±36.7)个月,主要并发症、死亡率在TEVAR组分别为7.0%、5.3%,药物组分别为6.6%、8.1%;术后1、2、4、7年累积生存率在TEVAR组分别为100%、97.1%、93.5%、78.0%,药物组分别为98.4%、96.4%、90.8%、72.7%,两组间差异无统计学意义(x2=0.019,P=0.890).结论 与单纯药物治疗相比,TEVAR术治疗稳定型Standford B型主动脉夹层可降低假腔扩展率,但有手术相关并发症,并不能提高生存率.

关 键 词:胸降主动脉  夹层  胸主动脉腔内修复术  药物治疗  覆膜支架

Endovascular repair or medication for the management of uncomplicated type B aortic dissection
WANG Jiangyun,CHEN Yong,LI Yanhao,HE Xiaofeng,ZENG Qingle,ZHAO Jianbo.Endovascular repair or medication for the management of uncomplicated type B aortic dissection[J].Journal of Interventional Radiology,2017,26(3).
Authors:WANG Jiangyun  CHEN Yong  LI Yanhao  HE Xiaofeng  ZENG Qingle  ZHAO Jianbo
Abstract:Objective To compare the curative effect of thoracic endovascular repair (TEVAR) plus medication with that of pure medication in treating uncomplicated type B aortic dissection,and to discuss the treatment strategy for uncomplicated type B aortic dissection.Methods The clinical data of 118 patients with definitely confirmed uncomplicated type B aortic dissection,who were admitted to authors' hospital during the period from 2004 to 2015,were retrospectively analyzed.Among the 118 patients,57 patients received TEVAR plus medication (TEVAR group) and 61 patients were treated with pure medication (drug group).The complications and mortality within one month and during follow-up period in both groups were calculated respectively,and Kaplan-Meier survival curves were used to compare the survival rate between the two groups.Results The incidences of complications and morbidity during hospitalization and within one month after treatment in TEVAR group were 5.2% and 0% respectively,which in the drug group were 0% and 0% respectively.The patients were followed up for 1-110 months,with a mean of (43.3±36.7) months.The incidence of main complications and the mortality in TEVAR group were 7.0% and 5.3% respectively,which in the drug group were 6.6% and 8.1% respectively.The one-,2-,4-and 7-year cumulative survival rates in TEVAR group were 100%,97.1%,93.5% and 78.0% respectively,which in the drug group were 98.4%,96.4%,90.8% and 72.7% respectively,the differences between the two groups were not statistically significant (~=0.019,P=0.890).Conclusion For the treatment of uncomplicated type B aortic dissection,TEVAR plus medication is superior to pure drug therapy in reducing expansion rate of false cavity,but TEVAR carries some procedure-related complications,besides,TEVAR can not improve the survival rate.(J Intervent Radiol,2017,26:266-269)
Keywords:thoracic descending aorta  dissection  thoracic aorta endovascular repair  medication  covered stent
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号